Institutional Repository in Medical Sciences
(IRMS – Nicolae Testemițanu SUMPh)

Lung transplantation in the management of cystic fibrosis

Show simple item record

dc.contributor.author Rotaru, Ludmila
dc.contributor.author Rotaru, Tudor
dc.date.accessioned 2026-04-03T15:49:52Z
dc.date.available 2026-04-03T15:49:52Z
dc.date.issued 2026
dc.identifier.citation ROTARU, Ludmila and Tudor ROTARU. Lung transplantation in the management of cystic fibrosis. In: Cells and Tissues Transplantation. Actualities and Perspectives: The Materials of the National Scientific Conference with International Participation, the 4 th edition, Chisinau, March 20-21, 2026. Chișinău : CEP Medicina, 2026, p. 53. ISBN 978-9975-82-477-4 (PDF). en_US
dc.identifier.isbn 978-9975-82-477-4
dc.identifier.uri https://repository.usmf.md/handle/20.500.12710/33044
dc.description.abstract Introduction. Cystic fibrosis (CF) is an autosomal recessive genetic disorder caused by mutations in the CFTR gene, affecting multiple organs, particularly the lungs, and leading to progressive respiratory failure. Despite therapeutic advances, some patients progress to advanced stages of the disease, for whom lung transplantation represents the only option with a significant impact on survival. Materials and Methods. A narrative synthesis of specialized literature was conducted using GeneCards, PubMed, the National Library of Medicine, and Hinari, focusing on publications from the past 10 years. Results. Analysis of the specialized literature indicates that lung transplantation in patients with advanced CF leads to significant improvements in respiratory function and quality of life. Posttransplant survival is estimated at 80–90% at one year, 78–82.8% at three years, and 69–77% at five years, while long-term survival at 10 years ranges between 50–62%, with a median of approximately 10–10.7 years. Clinical factors, including chronic infections and post-transplant rejection, influence prognosis, whereas lung retransplantation is associated with lower survival compared to primary transplantation, highlighting the importance of rigorous patient selection and optimal timing of intervention. Optimization of perioperative management and personalized immunosuppressive therapy contributes to complication reduction and improved survival. Multidisciplinary coordination of patient management further enhances clinical outcomes and long-term survival. Conclusions. Lung transplantation represents an essential intervention for patients with advanced CF, significantly improving life expectancy. Rigorous perioperative management, personalized immunosuppressive therapy, and multidisciplinary coordination contribute to the reduction of postoperative complications and improved clinical outcomes. Post-transplant risks persist, requiring continuous monitoring and adaptive interventions. en_US
dc.language.iso en en_US
dc.publisher CEP Medicina en_US
dc.relation.ispartof Cells and Tissues Transplantation. Actualities and Perspectives: The Materials of the National Scientific Conference with International Participation, the 4 th edition, Chisinau, March 20-21, 2026 en_US
dc.subject Cystic fibrosis en_US
dc.subject lung transplantation en_US
dc.subject post-transplant survival en_US
dc.title Lung transplantation in the management of cystic fibrosis en_US
dc.type Other en_US


Files in this item

This item appears in the following Collection(s)

Show simple item record

Search DSpace


Advanced Search

Browse

My Account

Statistics